Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Oculus Innovative Sciences Expands Regulatory Claims for Microcyn-Based Advanced Wound Management Products in Europe



Oculus Innovative Sciences Expands Regulatory Claims for Microcyn-Based
Advanced Wound Management Products in Europe

Upgraded Class III CE Mark to Include Claim of Reduction of Microorganisms

PETALUMA, Calif., March 26, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS) a healthcare company a global healthcare company
that designs, manufactures and markets prescription and non-prescription
products in over 20 countries, today announced that is has been granted a
reclassification of the company's CE Mark for the European formulation
Dermacyn™ Wound Care. The reclassification was approved by the British
Standards Institution (BSI), which is the world's largest certification body,
and the Medicines and Healthcare products Regulatory Agency (MHRA) in the
United Kingdom.  Reclassified as a class III medical device, the newest
indication is for "use in the debridement, irrigation and moistening of acute
and chronic wounds, ulcers, cuts, abrasions and burns. Through reducing the
amount of microorganisms and contributing to a moist environment, it enables
the body to perform its own healing process."  Additionally, the actives in
Dermacyn™ are classified in Europe as medicinal substances that may have a
local antimicrobial effect.

"This expanded label indication strengthens our European partners' product
portfolios since they now are able to discuss the issue of antimicrobial
effectiveness of Dermacyn in the wound bed with EU medical professionals,"
said Bruce Thornton, Oculus EVP of international operations. "This will
provide doctors with a safe and effective alternative to more costly and toxic
wound care regimens, thus improving patient outcomes."

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs,
manufactures and markets prescription and non-prescription products in over 20
countries. The company's products are used to treat patients in
surgical/advanced wound care, dermatology, women's health and animal health;
addressing the unmet medical needs of these markets—while raising the standard
of patient care and lowering overall healthcare costs.  The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found
at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and future financial
performance. These forward-looking statements are identified by the use of
words such as "strengthens," "improving" and "will provide," among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, including such risks that regulatory clinical and guideline
developments may change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals, clinical results may not be replicated in actual patient
settings, protection offered by the Company's patents and patent applications
may be challenged, invalidated or circumvented by its competitors, the
available market for the Company's products will not be as large as
expected, the Company's products will not be able to penetrate one or more
targeted markets, revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet its future capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for the year
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:
        
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         Vice President of Public and Investor Relations
         (425) 753-2105
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement